



FOR IMMEDIATE RELEASE

Public Relations Contact:

Simona Buergi
HemCon Medical Technologies Inc.
503-245-0459
simona.buergi@hemcon.com

HemCon Medical Technologies, Inc. and Zeria Pharmaceuticals Co. Ltd sign exclusive licensing agreement for HemCon’s innovative product line in Japan

Medical Innovators Partner to Bring Advanced Wound and Critical Care Products to Japanese Market

PORTLAND, Ore. — April 9, 2010 — [HemCon Medical Technologies, Inc.](#) (“HemCon”), an innovative developer of advanced medical products, is proud to announce the signing of an exclusive licensing agreement with [Zeria Pharmaceuticals Co. Ltd.](#) (“Zeria”), a leading pharmaceutical and consumer healthcare products company. Through this partnership, Zeria will market, distribute, and sell HemCon’s line of revolutionary wound and oral care dressings throughout Japan.

HemCon’s product offerings include a full line of [hemostatic dressings with antibacterial properties](#). The technology, originally developed for use on the battlefield to control severe hemorrhaging, is now used in acute care settings worldwide for bleeding control, wound management, and infection prevention. The HemCon line also includes an [over-the-counter line](#) of hemostatic products, as well as a revolutionary [oral wound care dressing](#) for oral surgery and periodontal procedures.

Zeria, established in 1955 and listed on the Tokyo Stock Exchange, has a wide-ranging portfolio that includes hemostatic surgical compounds, which the HemCon products will augment. Zeria holds a strong position in the gastroenterology (GI) field and markets products in dermatology and cardiovascular disease. The company also markets a range of consumer healthcare products and medications.

Zeria’s partnership with HemCon will allow them to strategically expand their product offering and market reach in the wound care, surgery, oral care, and patient safety markets. “Zeria will be establishing a separate division to specifically manage the HemCon product line as a new pillar in Zeria’s business.” said Zeria President and CEO Sachiaki Ibe

“HemCon is proud to be partnering with Zeria, one of the most well-balanced operating companies in the Japanese health care arena, to bring our advanced wound care products to the Japanese market,” said HemCon CEO John W. Morgan. “This partnership will also give HemCon the opportunity to break into the Asian market, which has not been the company’s focus until now, and represents a significant opportunity to help provide unique solutions for patient safety and wound care in Japan.”

About HemCon Medical Technologies Inc.

HemCon Medical Technologies Inc. is a leading global developer of advanced medical products designed to improve the standard of patient care. The company is responsible for developing the chitosan-based HemCon dressing used by thousands of military and civilian first responders and is changing wound care best practices in hospital, dental and clinical settings. In addition, HemCon is leading the charge to develop and license unique, life-saving medical advances including lyophilized human plasma and nanofiber technologies for wound care. HemCon is headquartered in Portland, Ore., with additional commercial operations in Ireland, England, Germany and the Czech Republic. For more information, please visit www.hemcon.com.

###